C4X Discovery CEO to be interim chair of UK Vaccine Taskforce

Drug discovery company C4X Discovery confirmed on Tuesday that its chief executive officer Clive Dix has stepped into the role of interim chair of the UK Vaccine Taskforce.

The taskforce is a group set up by the government to lead the country’s efforts to find and manufacture a Covid-19 vaccine.

It would set out arrangements for the long-term leadership of the Vaccine Taskforce shortly.

The AIM-traded firm said Dix was delivering on the company’s strategy to advance its portfolio, adding that the appointment would not impact his day-to-day role as CEO.

“The taskforce has worked tirelessly to seek and secure new vaccines for Covid-19,” said C4X chairman Eva-Lotta Allan.

“This important work has resulted in the UK being at the forefront of both receiving and developing these critical vaccines and demonstrates the expertise and drive of all those involved.

“As Kate Bingham has reached the end of her agreed tenure as chair, to ensure the smooth continuity of the work carried out by the taskforce, Clive is stepping into the role as chair for an interim period.”

Allan said Dix was delivering “strong” leadership at C4X, with a recent fundraise of £15m, which provided a “strong foundation” to continue driving focussed progress across its core portfolio.

“We look forward to providing a more in-depth update at our preliminary results later this month.”

At 0845 GMT, shares in C4X Discovery Holdings were down 1.88% at 18.25p.